Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDT Conduit Pharmaceuticals	$3.48 -15.3%	$9.16	$3.25 ▼ $4,905.00	$39.46M	2.39	111,774 shs	182,359 shs
CMND Clearmind Medicine	$0.97 -3.5%	$1.01	$0.85 ▼ $2.30	$4.12M	0.89	880,472 shs	24,818 shs
SXTC China SXT Pharmaceuticals	$1.55 -3.7%	$2.18	$0.95 ▼ $11.92	$1.12M	1.24	1.14 million shs	174,256 shs
TCRT Alaunos Therapeutics	$2.66 +0.8%	$2.48	$1.31 ▼ $11.50	$4.36M	-1.08	136,848 shs	3,912 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDT Conduit Pharmaceuticals	0.00%	-40.51%	-57.08%	-79.83%	-99.92%
CMND Clearmind Medicine	0.00%	-2.53%	-1.53%	-25.19%	-16.81%
SXTC China SXT Pharmaceuticals	0.00%	+29.17%	-1.90%	-43.36%	-81.55%
TCRT Alaunos Therapeutics	0.00%	-6.34%	-0.75%	+58.33%	-74.42%

Compare MarketRank™

Company	Overall Score	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDT Conduit Pharmaceuticals	0.711 of 5 stars	4.0	2.0	1.7	0.0
CMND Clearmind Medicine	0.1316 of 5 stars	2.0	0.6	1.7	0.0
SXTC China SXT Pharmaceuticals	0.2663 of 5 stars	3.0	1.1	0.0	0.6
TCRT Alaunos Therapeutics	0.4179 of 5 stars	5.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDT Conduit Pharmaceuticals	4.00	Strong Buy	N/A	N/A
CMND Clearmind Medicine	0.00	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
TCRT Alaunos Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDT Conduit Pharmaceuticals	N/A	N/A	N/A	N/A	($0.62) per share	N/A
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	$0.73 per share	N/A
SXTC China SXT Pharmaceuticals	$1.82M	0.62	N/A	N/A	$30.46 per share	0.05
TCRT Alaunos Therapeutics	$10K	436.24	N/A	N/A	$3.93 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDT Conduit Pharmaceuticals	-$540K	-$35.65	N/A	∞	N/A	N/A	N/A	-328.67%	N/A
CMND Clearmind Medicine	-$5.26M	-$1.22	N/A	∞	N/A	N/A	-129.21%	-61.15%	6/12/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	-$35.14M	N/A	0.00	∞	N/A	N/A	-267.77%	-209.18%	8/12/2025 (Estimated)

Latest SXTC, CMND, TCRT, and CDT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	CDT Conduit Pharmaceuticals	N/A	-$19.80	N/A	-$1.32	N/A	N/A
5/15/2025	Q1 2025	TCRT Alaunos Therapeutics	-$4.50	-$0.67	+$3.83	-$0.67	N/A	$0.00 million
3/28/2025	Q4 2024	CDT Conduit Pharmaceuticals	N/A	-$304.95	N/A	-$20.33	N/A	N/A
3/13/2025	Q1 2025	CMND Clearmind Medicine	N/A	-$0.24	N/A	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDT Conduit Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDT Conduit Pharmaceuticals	N/A	0.12	0.12
CMND Clearmind Medicine	0.01	1.72	1.72
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	4.30	4.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDT Conduit Pharmaceuticals	3.29%
CMND Clearmind Medicine	96.05%
SXTC China SXT Pharmaceuticals	5.02%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
CDT Conduit Pharmaceuticals	30.93%
CMND Clearmind Medicine	N/A
SXTC China SXT Pharmaceuticals	3.95%
TCRT Alaunos Therapeutics	5.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDT Conduit Pharmaceuticals	3	11.34 million	710,000	Not Optionable
CMND Clearmind Medicine	N/A	4.27 million	N/A	Not Optionable
SXTC China SXT Pharmaceuticals	90	723,000	3.90 million	Not Optionable
TCRT Alaunos Therapeutics	40	1.64 million	1.52 million	No Data

SXTC, CMND, TCRT, and CDT Headlines

Recent News About These Companies

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14, 2025 | globenewswire.com

Alaunos Therapeutics announces board member resignation

April 20, 2025 | investing.com

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

April 7, 2025 | msn.com

Precigen Terminates License Agreement With Alaunos Therapeutics

October 11, 2024 | marketwatch.com

After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen

October 11, 2024 | fiercebiotech.com

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

October 11, 2024 | finance.yahoo.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest Report

September 26, 2024 | benzinga.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News Summary

September 26, 2024 | benzinga.com

Stella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo Finance

September 24, 2024 | finance.yahoo.com

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024

May 16, 2024 | investorplace.com

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

April 12, 2024 | seekingalpha.com

TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023

April 8, 2024 | investorplace.com

Biora Therapeutics announces $6M registered direct offering and concurrent private placement

April 1, 2024 | msn.com

Sharp increase in TCRT’s short interest leads to surge in days-to-cover ratio

February 1, 2024 | knoxdaily.com

Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split

January 31, 2024 | msn.com

Werewolf Therapeutics Inc (HOWL)

January 31, 2024 | investing.com

Alaunos Therapeutics Inc [TCRT] Insider Boyle Kevin S. Sr. sells 68,014 Shares – Latest Insider Activity

January 3, 2024 | knoxdaily.com

Alaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and Dates

December 28, 2023 | benzinga.com

TCRT Shares Experience Decline in Value

November 17, 2023 | knoxdaily.com

Recap: Alaunos Therapeutics Q3 Earnings

November 14, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, CMND, TCRT, and CDT Company Descriptions

Conduit Pharmaceuticals NASDAQ:CDT

$3.48 -0.63 (-15.33%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$3.57 +0.09 (+2.61%)

As of 05/23/2025 07:54 PM Eastern

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Clearmind Medicine NASDAQ:CMND

$0.96 -0.04 (-3.50%)

Closing price 05/23/2025 03:52 PM Eastern

Extended Trading

$0.96 -0.01 (-0.83%)

As of 05/23/2025 05:34 PM Eastern

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.55 -0.06 (-3.73%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.01 (+0.97%)

As of 05/23/2025 07:13 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Alaunos Therapeutics NASDAQ:TCRT

$2.66 +0.02 (+0.76%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$2.54 -0.12 (-4.47%)

As of 05/23/2025 06:55 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time